A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)
A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)
This is a screening study to detect BRAF V600 mutation-positive patients for enrollment into
 clinical research studies of Zelboraf (vemurafenib). Tumor samples will be collected and
 analyzed from eligible patients with solid tumors (other than metastatic melanoma or
 papillary thyroid cancer) or multiple myeloma. All institutions with identified patients as
 defined by this screening protocol will have potential access to the separate vemurafenib
 protocol MO28072.
Inclusion Criteria:

 -  Histologically confirmed solid tumors (excluding melanoma and papillary thyroid
 cancer) or multiple myeloma refractory to standard therapy or for which standard or
 curative therapy does not exist or is not considered appropriate by the investigator

 -  Patients with multiple myeloma must have received at least one line of prior systemic
 therapy for the treatment of multiple myeloma

 Exclusion Criteria:

 -  Eastern Cooperative Oncology Group (ECOG) performance status > 2

 -  Uncontrolled concurrent malignancy

 -  Active or untreated CNS metastases

 -  History of known carcinomatous meningitis

 -  Prior treatment with a BRAF or MEK inhibitor (prior sorafenib is allowed)

 -  Uncontrolled, severe medical illness or condition as defined in protocol MO28072